Immunovia AB (publ) (IMMNOV.ST)
SEK 0.66
(1.23%)
SEK 0.66
(1.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -166.55 Million SEK | -17.64% |
| 2022 | -141.57 Million SEK | -4.51% |
| 2021 | -135.47 Million SEK | -0.46% |
| 2020 | -134.85 Million SEK | -28.73% |
| 2019 | -104.75 Million SEK | -25.07% |
| 2018 | -83.75 Million SEK | -90.53% |
| 2017 | -43.96 Million SEK | -210.15% |
| 2016 | -14.19 Million SEK | -99.78% |
| 2015 | -7.09 Million SEK | 14.49% |
| 2014 | -8.59 Million SEK | -658.46% |
| 2013 | -1.09 Million SEK | -57928.59% |
| 2012 | -1885.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 181 Thousand SEK | 100.57% |
| 2024 Q2 | -22.37 Million SEK | -12425.97% |
| 2023 FY | - SEK | -17.64% |
| 2023 Q2 | -38.84 Million SEK | 8.76% |
| 2023 Q1 | -42.57 Million SEK | 29.87% |
| 2023 Q3 | -35.42 Million SEK | 8.82% |
| 2023 Q4 | -49.71 Million SEK | -40.34% |
| 2022 Q3 | -16.41 Million SEK | 39.17% |
| 2022 FY | - SEK | -4.51% |
| 2022 Q4 | -60.7 Million SEK | -269.93% |
| 2022 Q2 | -26.97 Million SEK | 28.04% |
| 2022 Q1 | -37.48 Million SEK | 12.73% |
| 2021 Q3 | -29.56 Million SEK | 30.67% |
| 2021 Q1 | -20.3 Million SEK | 60.49% |
| 2021 Q2 | -42.64 Million SEK | -110.0% |
| 2021 FY | - SEK | -0.46% |
| 2021 Q4 | -42.95 Million SEK | -45.28% |
| 2020 FY | - SEK | -28.73% |
| 2020 Q1 | -24.96 Million SEK | 17.16% |
| 2020 Q2 | -26.17 Million SEK | -4.85% |
| 2020 Q4 | -51.39 Million SEK | -56.94% |
| 2020 Q3 | -32.75 Million SEK | -25.14% |
| 2019 Q2 | -27.42 Million SEK | -14.34% |
| 2019 Q4 | -30.12 Million SEK | -29.94% |
| 2019 Q1 | -23.99 Million SEK | 4.23% |
| 2019 FY | - SEK | -25.07% |
| 2019 Q3 | -23.18 Million SEK | 15.47% |
| 2018 FY | - SEK | -90.53% |
| 2018 Q4 | -25.05 Million SEK | -52.2% |
| 2018 Q3 | -16.45 Million SEK | 35.34% |
| 2018 Q1 | -16.79 Million SEK | -12.52% |
| 2018 Q2 | -25.45 Million SEK | -51.61% |
| 2017 Q1 | -7.53 Million SEK | -46.79% |
| 2017 FY | - SEK | -210.15% |
| 2017 Q4 | -14.92 Million SEK | -33.0% |
| 2017 Q3 | -11.21 Million SEK | -9.07% |
| 2017 Q2 | -10.28 Million SEK | -36.58% |
| 2016 Q3 | -3.92 Million SEK | -40.09% |
| 2016 Q4 | -5.13 Million SEK | -30.84% |
| 2016 FY | - SEK | -99.78% |
| 2016 Q2 | -2.79 Million SEK | -20.54% |
| 2016 Q1 | -2.32 Million SEK | -34.85% |
| 2015 FY | - SEK | 14.49% |
| 2015 Q4 | -1.72 Million SEK | 0.0% |
| 2015 Q1 | -1.84 Million SEK | 37.44% |
| 2015 Q3 | -1.72 Million SEK | 6.72% |
| 2015 Q2 | -1.84 Million SEK | 0.0% |
| 2014 Q4 | -2.95 Million SEK | 0.0% |
| 2014 Q1 | -1.39 Million SEK | 0.0% |
| 2014 Q2 | -1.39 Million SEK | 0.0% |
| 2014 Q3 | -2.95 Million SEK | -110.86% |
| 2014 FY | - SEK | -658.46% |
| 2013 FY | - SEK | -57928.59% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AroCell AB (publ) | -13.75 Million SEK | -1110.546% |
| Devyser Diagnostics AB (publ) | -43.8 Million SEK | -280.272% |
| Prostatype Genomics AB (publ) | -38.02 Million SEK | -338.083% |
| SenzaGen AB | -13.53 Million SEK | -1130.489% |
| Spermosens AB | -10.7 Million SEK | -1456.044% |